Please use this identifier to cite or link to this item:
Title: Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Author: Bellet, Meritxell
Ahmad, Faten
Villanueva, Rafael
Valdivia, Carolina
Palomino Doza, Julián
Ruiz, Ada
González, Xavier
Adrover, Encarna
Azaro, Analía
Valls Margarit, Maria
Parra, Josep Lluís
Aguilar Company, Juan
Vidal, Maria
Martin, Anastasi
Gavilá, Joaquín
Escrivá de Romaní, Santiago
Perelló, Antonia
Hernando, Cristina
Lahuerta, Ainhara
Zamora, Pilar
Reyes, Victoria
Alcalde, María
Masanas, Helena
Celiz, Pamela
Ruiz, Isabel
Gil Gil, Miguel
Seguí, Miguel Àngel
Peña, Lorena de la
Keywords: Càncer de mama
Breast cancer
Issue Date: 1-May-2019
Publisher: Sage Publications Ltd.
Abstract: Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
Note: Reproducció del document publicat a:
It is part of: Therapeutic Advances in Medical Oncology, 2019, vol. 11
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
BelletM.pdf556.88 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons